apolipoprotein A-I mimetic peptide

Apolipoprotein A-I mimetic peptides (ApoAI MP) are synthetic peptides designed to replicate the functional properties of the full-length apolipoprotein A-I (ApoA-I) protein, the primary protein component of high-density lipoprotein (HDL). These peptides, typically characterized by amphipathic alpha-helical structures, exert potent antioxidant and anti-inflammatory effects by binding and sequestering pro-inflammatory oxidized phospholipids and scavenging reactive oxygen species (ROS). In preclinical models of Parkinson's disease, ApoAI MP has demonstrated neuroprotective potential by reducing oxidative stress markers (such as hydrogen peroxide and superoxide anions) and suppressing the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and interleukin-6 (IL-6). Furthermore, these mimetics have been shown to enhance the activity of endogenous antioxidant enzymes like superoxide dismutase (SOD) and catalase, leading to improved motor coordination and behavioral performance in animal models.

Other names

ApoAI MPApoA-I mimetic peptideApolipoprotein A-I mimetic peptideApoAI-MP